Active Substance: Dexlansoprazole.

UAD , based on 7541 reviews.
View Drug details

Welcome to Dwaey, specifically on DEXILANT 30mg Capsules (Hard Gelatin)/Modified Release page.
This medicine contains an important and useful components, as it consists of Dexlansoprazole.
DEXILANT 30mg is available in the market in concentration 30mg/Capsule and in the form of Capsules (Hard Gelatin)/Modified Release.

TAKEDA PHARMACEUTICALS U.S.A., INC. is the producer of DEXILANT 30mg and it is imported from USA, The most popular alternatives of DEXILANT 30mg are listed downward .

Mode Of Action & Indication

R-enantiomer of lansoprazole; PPI; binds to H+/K+-exchanging ATPase (proton pump) in gastric parietal cells, resulting in blockage of acid secretion.Dual release formulation.

  • Oesophagitis
  • Gastro-oesophageal reflux disease (GERD)

Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation. Lactation: Not known whether distributed into breast milk; discontinue nursing or drug

Side Effects
  • 1-10% Diarrhea (5%)
  • Abdominal pain (4%)
  • Nausea (3%)
  • URI (2-3%)
  • Vomiting (1-2%)
  • Flatulence (1%) <1% (Selected) Arrhythmia
  • Bradycardia
  • Barrett's esophagus
  • DVT
  • Dyspnea
  • Hepatomegaly
  • Hypertension
  • Paresthesia
  • Rectal hemorrhage
  • Vulvovaginal infection
Alternatives Price List
  • DEXILANT 60mgUAD 122
  • DEXILANT 60mgUAD 201
  • DEXILANT 30mgUAD 90
  • DEXILANT 30mgUAD 147
Contra indication


Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.


Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate. Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.

Releated Products


Report Price Error

Please feel welcome to contact Us with any price or medical error. Our doctors will receive any reports.